Scott Cohen co-wrote this blog post with Namita Kalyan.
You may have heard this old adage: Three frogs are sitting on a log. One of them decides to leap off. How many frogs are left on the log? The answer is still three frogs. There’s a difference between deciding to do something and actually doing it—and that difference is execution.
After initial concerns and disappointing studies in the 1980s to early 2000s, cell and gene therapies are now at the forefront of medicine, displaying unprecedented efficacy in a number of clinical trials. As more trials occur, the patient success stories are growing, and an increasing number of manufacturers are investing or partnering to develop more of these next-wave cancer medicines. In 2015, close to 100 clinical trials involving CAR (chimeric antigen receptor) T-cell therapies were under development, according to the Journal of Immunology Research.